Continuous renal replacement therapy (CRRT) program initiation in PICU of a resource limited setting: a retrospective analysis of challenges and outcomes.

Publication date: Jul 14, 2025

Continuous Renal Replacement Therapy (CRRT) is emerging as an essential component of organ support in critically ill children. In low- and middle- income countries (LMIC), limited resources, lack of technical support, cost, and administrative issues are major barriers in initiating and sustaining a CRRT program. A core team, comprising a consultant and two pediatric intensive care fellows, was assigned additional responsibility of initiating and sustaining a CRRT program in the PICU of a tertiary care teaching and referral hospital. We retrospectively reviewed the data from initiation in February 2019 till May 2023 to understand the indications, prescription details, challenges, and their relation to outcomes. During this period, 52 children with mean (SD) age of 7. 6 (3. 2) years and median (IQR) weight of 20 (17, 30) kg underwent CRRT in 71 sessions. The mean PRISM-III score was 18 (5. 2), with 98. 1% having multiorgan dysfunction at CRRT initiation. Acute kidney injury (53. 8%), hyperammonemia (21. 2%), and a combination of both (17. 3%) were common indications. Continuous venovenous hemodiafiltration was the most used modality (61. 5%). Median CRRT duration was 36 (20. 3, 58) hours. Filter usage averaged 1. 4 per patient with a median life of 35 (17, 48) hours, improving from 24 to 36 h over time. Filter clotting (33. 8%), access flow issues (7%), and hemodynamic instability (4. 2%) were complications encountered. Survival to discharge was 25%, with serum lactate [Formula: see text]3 mmol/L at CRRT initiation being an independent predictor of mortality (adjusted OR 6. 1, 95% CI: 1. 1-34. 9; P = 0. 04). Major challenges faced in our program included the SARS-CoV-2 pandemic, non-availability of technical support, and out-of-pocket expenses. These were circumvented by involvement of fellows and nurses, training them with internal and external experts, and mobilizing resources from governmental and non-governmental organizations. Initiating a CRRT program in LMICs is feasible despite challenges. Creating a team with members willing to shoulder additional responsibility and training them gave impetus to our program. Tapping governmental and non-governmental support helped us circumvent financial challenges. However, in a resource limited setting, sustainability requires in-house technical and financial support. Survival to discharge was 25%, with hyperlactatemia at CRRT initiation predicting mortality.

Open Access PDF

Concepts Keywords
February Acute Kidney Injury
Hemodynamic Acute kidney injury
Kidney Child
Nurses Child, Preschool
Pandemic Critical Illness
Developing Countries
Female
Filter life
Financial constraints
Healthcare delivery challenges
Human resource constraints
Humans
Infant
Male
Multiorgan dysfunction
Retrospective Studies
Sustainability
Treatment Outcome

Semantics

Type Source Name
disease MESH critically ill
disease MESH Acute kidney injury
disease MESH hyperammonemia
disease MESH complications
disease MESH hyperlactatemia
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH acute liver failure
disease MESH inborn errors metabolism
disease IDO blood
drug DRUGBANK Trestolone
disease IDO process
disease MESH COVID 19 pandemic
drug DRUGBANK Honey
drug DRUGBANK Sulpiride
disease IDO site
drug DRUGBANK Potassium
drug DRUGBANK Heparin
drug DRUGBANK Calcium
disease MESH MODS
disease MESH Sepsis
drug DRUGBANK Creatinine
disease MESH Kidney Disease
drug DRUGBANK Urea
drug DRUGBANK Ammonia
drug DRUGBANK Magnesium
drug DRUGBANK Indoleacetic acid
disease MESH infections
disease MESH chronic kidney disease
drug DRUGBANK Serine
disease MESH DKA diabetic ketoacidosis
disease MESH syndrome
disease MESH acute respiratory distress syndrome
drug DRUGBANK Mitomycin
drug DRUGBANK Hexachlorophene
disease MESH morbidity
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Guanosine
disease MESH septic shock
drug DRUGBANK Amlodipine

Original Article

(Visited 3 times, 1 visits today)